CHT Wound Care & Hyperbaric Indications Flashcards
6 cards from real CHT practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 CHT Wound Care & Hyperbaric Indications flashcards as text
Which diabetic foot wound classification qualifies for HBOT under UHMS-approved indications?
Answer: Wagner Grade III or higher wound with demonstrated tissue hypoxia
UHMS approves HBOT for Wagner Grade III or higher diabetic foot wounds with documented tissue hypoxia that has not responded to standard wound care.
A transcutaneous oxygen measurement (TCOM/TcPO2) below what value indicates severe tissue hypoxia and poor healing potential?
Answer: 25 mmHg
A periwound TCOM below 25 mmHg indicates severe tissue hypoxia and predicts poor wound healing without an oxygen-enhancing intervention such as HBOT.
HBOT promotes wound healing primarily by:
Answer: Raising tissue oxygen tension to stimulate angiogenesis, fibroblast activity, and collagen synthesis
HBOT elevates tissue PO2, which stimulates fibroblast proliferation, collagen deposition, and VEGF-driven angiogenesis — all critical steps in wound healing.
Carbon monoxide poisoning is treated with HBOT because:
Answer: Oxygen at high partial pressure competitively displaces CO from hemoglobin, reducing carboxyhemoglobin half-life from ~5 hours to ~20 minutes
At 2.4–3 ATA, high PO2 competitively displaces CO from hemoglobin and myoglobin, dramatically accelerating CO elimination and reducing delayed neurological injury.
Which type of radiation injury is an approved UHMS indication for HBOT?
Answer: Delayed radiation necrosis of soft tissue and bone (osteoradionecrosis)
Delayed radiation necrosis (soft tissue radionecrosis and osteoradionecrosis) is UHMS-approved because radiation causes progressive vascular obliteration leading to chronic tissue hypoxia.
Compromised skin grafts and flaps are treated with HBOT to:
Answer: Enhance tissue oxygenation and neovascularization to improve graft and flap survival
HBOT enhances tissue PO2 and stimulates VEGF-driven neovascularization, improving perfusion to marginally viable grafts and flaps to prevent necrosis.